1. France Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Ipsen S.A.

Ipsen S.A.

IPSEY
Ipsen S.A.US flagOther OTC
43.20
USD
-1.25
- -
57.13BMarket Cap
Ipsen S.A.
IPSEY
(Other OTC)

Recent

price

43.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
3.46
3.64
3.84
3.86
4.06
4.62
5.08
6.09
7.08
8.1
8.09
8.31
9.58
9.99
10.8
- -
Revenue per Share
0.28
- -
-0.08
0.46
0.47
0.58
0.69
0.82
1.17
-0.15
1.65
1.96
1.97
1.95
1.04
- -
Basic EPS, GAAP
0.49
0.22
0.18
0.38
0.49
0.45
-0.17
0.55
0.85
1.04
1.9
1.44
2.18
2.05
0.4
- -
Free Cash Flow per Basic Share
0.18
0.2
0.2
0.2
0.2
0.21
0.21
0.21
0.25
0.25
0.25
0.25
0.3
0.3
0.3
- -
Dividend per Share
0.53
0.25
0.17
0.71
0.72
0.83
0.94
1.08
1.43
0.1
1.9
2.21
2.22
2.2
1.3
- -
Book Value per Share
1.82
1.71
1.43
1.56
1.77
2.19
1.9
0.66
1.31
-0.79
1.26
2.25
3.57
1.45
2.91
- -
Tangible Book Value per Share
338
333
333
332
328
329
329
330
332
332
332
331
330
331
331
- -
Basic Weighted Avg Shares
1,170
1,210
1,277
1,282
1,332
1,520
1,671
2,012
2,348
2,693
2,686
2,749
3,156
3,306
3,574
3,929
Sales/Revenue/Turnover
19.56
14.63
13.85
17.42
18.86
20.73
20.91
19.94
23.69
24.62
26.96
31.05
27.6
18.49
19.25
24.05
Operating Margin (%)
39
72
70
26
50
44
39
106
143
161
235
246
336
88
706
625
Depreciation Expense
95
- -
-28
152
154
190
226
272
390
-51
548
647
649
644
346
444
Net Income, GAAP
13.52
- -
20.56
29.43
26.08
20.99
24.68
27.35
21.88
- -
- -
20.06
15.9
17.89
17.35
23.09
Effective Tax Rate (%)
8.14
0.04
-2.19
11.9
11.52
12.49
13.52
13.54
16.59
-1.88
20.4
23.52
20.55
19.49
9.68
11.29
Profit Margin (%)
307
262
169
226
261
348
489
75
226
-106
366
725
1,062
272
516
1,384
Working Capital
15
- -
- -
- -
12
- -
297
298
298
696
639
658
582
337
390
832
LT Debt
1,079
1,004
905
974
1,068
1,226
1,362
1,536
1,843
1,753
2,134
2,738
3,343
3,824
4,182
4,337
Total Equity
18.65
- -
14.48
16.3
17.53
20.87
17.76
16.1
20.92
- -
- -
20.87
19.52
12.07
12.66
14.63
Return on Invested Capital (%)
40.71
- -
-31.33
99.8
61.73
69.39
50.72
41.59
51.67
- -
- -
45.4
48.74
55
38.74
42.32
Return on Capital (%)
45.35
0.32
-39.63
104.09
64.89
74.54
77.55
81.83
93.93
-20.02
164.84
94.93
88.68
88.24
59.75
92.69
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.86%
15.57%
3.71%
Free Cash Flow
3.81%
89.84%
508.8%
Net Income, GAAP
-121.18%
-0.09%
28.22%
Sales/Revenue/Turnover
10.14%
7.99%
9.92%
Total Cash Common Dividend
- -
- -
16.67%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
3,306
2024
- -
- -
- -
- -
3,574
2025
- -
- -
- -
- -
3,929

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.95
2024
- -
- -
- -
- -
1.04
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.3
2024
- -
- -
- -
- -
0.3
2025
- -
- -
- -
- -
- -
Similar Companies
Renhe Pharmacy Co., Ltd. (000650.SZ)
Wockhardt Limited (WOCKPHARMA.BO)
Ironwood Pharmaceuticals, Inc. (IRWD)
NeutriSci International Inc. (NRXCF)
Digicann Ventures Inc. (AGFAF)
Procyon Corporation (PCYN)
Business
Ipsen SA (IPSEY) operates as a global biopharmaceutical company focused on developing and commercializing innovative medicines in oncology, rare diseases, and neuroscience. The company offers a portfolio of specialty care products including Somatuline (lanreotide) for neuroendocrine tumors; Cabometyx (cabozantinib) for renal cell carcinoma, hepatocellular carcinoma, and thyroid cancers; Onivyde (irinotecan liposome injection) for pancreatic and ovarian cancers; Dysport (abobotulinumtoxinA) for movement disorders, spasticity, and aesthetic indications; Bylvay (odevixibat) for rare liver diseases such as progressive familial intrahepatic cholestasis; Tazverik (tazemetostat) for relapsed or refractory follicular lymphoma; and IQIRVO (elafibranor) for primary biliary cholangitis, with additional pipeline assets targeting rare bone disorders, growth disorders, rare neurogenetic conditions, and hematology-oncology indications. Ipsen conducts commercial operations in over 30 countries with products registered in 88 nations, emphasizing Europe, North America, and international markets; it maintains global R&D hubs in France, the U.S., and the U.K., supported by approximately 5,000 employees. Founded in 1929 as a family-owned business by Henri Beaufour and headquartered in Paris, France, Ipsen listed on Euronext Paris in 1983. Recent strategic developments include the October 2025 announcement to acquire ImCheck Therapeutics for up to €1 billion to bolster its oncology pipeline with ICT01, a gamma delta T-cell activator for solid tumors; expansion of partnerships in 2024 with Skyhawk Therapeutics on RNA modulators for rare neurological diseases, Marengo Therapeutics on T-cell engagers, and others such as Foreseen, Sutro Biopharma, Biomunex, and Day One Biopharmaceuticals for ex-U.S. rights to Ojemda (tovorafenib); prior acquisitions of Albireo in 2023 for Bylvay, Epizyme in 2022 for Tazverik, and Clementia in 2019 for palovarotene in rare bone diseases; divestment of its Consumer Healthcare business to Mayoly Spindler in 2022 to sharpen focus on specialty care; and upgrades to 2025 guidance projecting around 10% total sales growth driven by oncology and rare disease momentum, alongside approvals such as Cabometyx for advanced neuroendocrine tumors in the EU and Bylvay in Japan.

Company News

APIChat

  • seekingalpha.com

    Ipsen S.A. (IPSEY) Discusses Phase II LANTIC Data and Innovation in Engineered Neuroinhibitors for Aesthetic Indications Transcript

  • globenewswire.com

    Ipsen S.A. – Evolution of the composition of the Board of Directors

  • globenewswire.com

    Annual General Meeting of Ipsen S.A. held on 13 May 2026

  • seekingalpha.com

    Ipsen S.A. (IPSEY) Q1 2026 Earnings Call Transcript

  • defenseworld.net

    IPSEN (OTCMKTS:IPSEY) Shares Cross Above Two Hundred Day Moving Average – Should You Sell?

  • globenewswire.com

    Ipsen S.A. publishes its 2025 Consolidated Financial Statements

  • globenewswire.com

    GENFIT to receive US$20M milestone after Ipsen's Iqirvo® exceeds the US$200M threshold in its first full year of net sales

  • seekingalpha.com

    Ipsen S.A. (IPSEY) Q4 2025 Earnings Call Transcript

  • defenseworld.net

    IPSEN (OTCMKTS:IPSEY) Shares Gap Up – What’s Next?

  • defenseworld.net

    IPSEN (OTCMKTS:IPSEY) Shares Pass Above Two Hundred Day Moving Average – Time to Sell?

  • defenseworld.net

    IPSEN (OTCMKTS:IPSEY) Shares Pass Above 200 Day Moving Average – What’s Next?

  • seekingalpha.com

    Ipsen S.A. (IPSEY) Q3 2025 Earnings Call Transcript

  • globenewswire.com

    Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025)

  • globenewswire.com

    Ipsen S.A. - Initiation of the share buy-back program

  • globenewswire.com

    Ipsen S.A. - Annual General Meeting held on 21 May 2025

  • globenewswire.com

    GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in Italy

  • globenewswire.com

    Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting

  • seekingalpha.com

    Ipsen S.A. (IPSEY) Q1 2025 Earnings Call Transcript

  • seekingalpha.com

    Ipsen S.A. (IPSEY) Q4 2024 Earnings Call Transcript

  • globenewswire.com

    Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen